目的：观察萘普生栓在绝经后妇女取环中的作用。
AIM: To observe the application effect of naproxen on postmenopausal women with intrauterine device.
本文介绍了国内外对雌激素在绝经后妇女骨关节炎和骨质疏松中作用的研究成果。
In this paper the latest studies on the role of estrogen for the development of osteoarthritis and osteoporosis in postmenopausal women are reviewed.
研究显示，代谢综合征可增加女性乳腺癌的患病风险，在绝经后妇女中表现更明显。
There is growing data suggesting that metabolic syndrome may increase the incidence of breast cancer, especially in postmenopausal women.
骨质疏松症随年龄增长出现加速性骨质丧失且在绝经后妇女中特别常见，使其有骨折的风险(如髋骨、腕骨、椎骨)。
Osteoporosis is accelerated bone loss with age and is particularly common amongst postmenopausal women, putting them at risk for fractures (hip, wrist, vertebrae).
在绝经过渡期和绝经后数年，许多妇女会经历更年期症状。
Many women experience menopausal symptoms during the menopausal transition and postmenopausal years.
在一项研究中，绝经后每日服用1000毫克的钙的妇女降低了近一半的骨质损失速度。
In one study, postmenopausal women who took 1,000 milligrams of calcium daily lowered their rate of bone loss by almost half.
在2007年的临床试验中，意大利研究人员发现，染料木素补充剂，以及钙和维生素d，似乎有助提高绝经后妇女骨量。
In a 2007 clinical trial, Italian researchers found that genistein supplements, along with calcium and vitamin d, appeared to help boost bone mass in postmenopausal women.
在绝经后并且患有骨质疏松症的妇女中，颈动脉或者股动脉粥样硬化与低骨量之间的关系。骨保护素有作用吗。
The association between carotid or femoral atherosclerosis and low bone mass in postmenopausal women referred for osteoporosis screening. Does osteoprotegerin play a role?
在男性，绝经后妇女和儿童缺铁是有效保护的机构。
In men, post-menopausal women, and children iron is efficiently conserved by the body.
背景：关于肢端肥大症骨质疏松骨折的资料有限，在活动性肢端肥大症的绝经后妇女中，可以观察到放射线检测到的椎骨骨折发生率增加。
CONTEXT: Data on osteoporotic fractures in acromegaly are limited. An increased prevalence of radiological vertebral fractures was already observed in postmenopausal women with active acromegaly.
纳入健康的绝经后妇女，种族、国籍、地域不限，年龄在50 ~ 70岁之间。
Healthy postmenopausal women aged between 50-70 years were included, regardless of race, nationality, and region.
方法：选择年龄在50 ~60岁符合诊断标准的绝经后妇女30例。
Method: 30 cases of postmenopausal women (at the aged of 50 ~ 60 years) were selected with certain diagnostic standard.
该研究包括纳入参加“妇女健康行动临床试验”的36282名年龄在50-79岁之间的绝经后妇女。
The study included 36,282 postmenopausal women ages 50 to 79 years who were enrolled in the Women's Health Initiative clinical trial.
选择性雌激素受体调节剂是一类在不同的组织细胞中对雌激素受体发挥不同调节作用的化合物，用于治疗绝经后妇女的骨质疏松和乳腺癌等。
Selective estrogen receptor modulators (SERMs) are kinds of compounds that exert different biological effects on er in different tissues and can be used in the tr.
“在妇女健康启动项目研究计划中，妇女是在平均绝经期后13年开始进行HRT的，”Manglesdorf博士说。
"In the Women's Health Initiative research program, the women who began taking HRT were an average of 13 years postmenopause, " Dr. Manglesdorf said.
“在妇女健康启动项目研究计划中，妇女是在平均绝经期后13年开始进行HRT的，”Manglesdorf博士说。
"In the Women's Health Initiative research program, the women who began taking HRT were an average of 13 years postmenopause, " Dr. Manglesdorf said.
应用推荐